Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3865Neoplasms 2991Prostatic Neoplasms 1754Colorectal Neoplasms 1431Lung Neoplasms 1332Motor Activity 805Head and Neck Neoplasms 686Pancreatic Neoplasms 664Colonic Neoplasms 655Uterine Cervical Neoplasms 653Carcinoma, Hepatocellular 632Carcinoma, Non-Small-Cell Lung 631Rectal Neoplasms 571Stomach Neoplasms 547Brain Neoplasms 486Ovarian Neoplasms 441Anxiety Disorders 420Pain 419Neoplasm Metastasis 385Esophageal Neoplasms 384Polycystic Ovary Syndrome 376Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Urinary Bladder Neoplasms 351Fatigue 340Multiple Myeloma 323Melanoma 323Lymphoma 306Depression 306Endometrial Neoplasms 290Liver Neoplasms 280

Interventions

dalpiciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × HR+/HER2- Advanced Breast Cancer × Clear all
NCT06711094 2024-12-02

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

Fujian Medical University

Phase NA Not yet recruiting
52 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡